pdufa.bio
CalendarDecisionsApprovals/yrTrial oddsLearnResearchMethodology
Home › PDUFA Calendar › VNDA

VNDA PDUFA Date: Imsidolimab (ANB019)

FDA decision (PDUFA) target 2026-12-12 · Vanda Pharmaceuticals Inc. · Generalized pustular psoriasis

VNDA run-up into the PDUFA (last ~120 days)

$9.56$5.73
Price path to 2026-06-19. Green = local high, red = low/sell-off. Historical price action, not a forecast.

Key facts

FDA PDUFA target date2026-12-12
Drug / candidateImsidolimab (ANB019)
IndicationGeneralized pustular psoriasis
CompanyVanda Pharmaceuticals Inc.
Market-cap tierSmall
Cohort decision-day move (history)±3% median
ClinicalTrials.govNCT05352893 · nan

New to FDA decisions? Read what a PDUFA date is and how often the FDA approves drugs.

Track this live → price, options (expected move & IV) and the full dashboard
Opens the pdufa.bio app (private beta)

FAQ

When is the VNDA PDUFA date?
The FDA PDUFA target date for VNDA (Vanda Pharmaceuticals Inc.) is 2026-12-12 for Imsidolimab (ANB019). Dates are company/FDA-sourced and can slip — verify against primary filings.
What is VNDA's drug Imsidolimab (ANB019)?
Imsidolimab (ANB019) is Vanda Pharmaceuticals Inc.'s candidate under FDA review for Generalized pustular psoriasis.
What typically happens to a small-cap stock into a PDUFA date?
Historically, small-cap names had a median decision-day move around ±3% (694-PDUFA cohort, 2024–26). This is historical context by market-cap tier, not a prediction for this drug.